Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

Tirzepatide

Tirzepatide is a GIP- and GLP-1-receptor agonist. Approved delivery systems, concentrations, excipients, and labeling are not interchangeable with a research vial. Large product-development programs support specific branded uses; ongoing studies do not turn every metabolic claim into an approved indication.

Aliases reviewed
Mounjaro, Zepbound, Tirzepitide
Sources checked
2026-09-15
Editorial status
published

Evidence at a glance

Human
Not rated
Animal/cell
Not rated
Approved medicine
Approved product existsAn approved U.S. product (Mounjaro), for a specific formulation and use.

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. Trials examine glycemic, weight, cardiovascular, sleep-apnea, and other metabolic outcomes in defined populations.

Identity

Tirzepatide is a GIP- and GLP-1-receptor agonist. Approved delivery systems, concentrations, excipients, and labeling are not interchangeable with a research vial.

Biological mechanism or research interest

Trials examine glycemic, weight, cardiovascular, sleep-apnea, and other metabolic outcomes in defined populations.

Verified approved human uses

FDA-approved Mounjaro injection is labeled for glycemic control in adults and children aged 10 years and older with type 2 diabetes. Other branded indications require their own current labels. This catalogue vial is not an approved medicine.

Investigational human evidence

Large product-development programs support specific branded uses; ongoing studies do not turn every metabolic claim into an approved indication.

Claims must not be generalized across diabetes, obesity, cardiovascular risk, or other conditions without the matching product, population, and outcome evidence.

Human versus animal or cell evidence

Receptor pharmacology and animal findings help explain effects but labels depend on clinical trials.

Limitations and known risks

The Mounjaro label includes a boxed thyroid C-cell-tumor warning from rodent findings and gastrointestinal, pancreatitis, gallbladder, kidney-volume-depletion, hypoglycemia, and hypersensitivity risks.

What this profile is—and is not

Concise source review published with formulation, jurisdiction, and evidence-strength limits; recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.